IL132380A0 - Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods - Google Patents

Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods

Info

Publication number
IL132380A0
IL132380A0 IL13238098A IL13238098A IL132380A0 IL 132380 A0 IL132380 A0 IL 132380A0 IL 13238098 A IL13238098 A IL 13238098A IL 13238098 A IL13238098 A IL 13238098A IL 132380 A0 IL132380 A0 IL 132380A0
Authority
IL
Israel
Prior art keywords
protein
conjugates
antibody
compositions
chain
Prior art date
Application number
IL13238098A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/059,467 external-priority patent/US20020019352A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL132380A0 publication Critical patent/IL132380A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL13238098A 1997-04-17 1998-04-16 Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods IL132380A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84397197A 1997-04-17 1997-04-17
US09/059,467 US20020019352A1 (en) 1997-04-17 1998-04-14 Stable, active, human ob protein compositions and methods
PCT/US1998/007828 WO1998046257A1 (en) 1997-04-17 1998-04-16 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Publications (1)

Publication Number Publication Date
IL132380A0 true IL132380A0 (en) 2001-03-19

Family

ID=26738785

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13238098A IL132380A0 (en) 1997-04-17 1998-04-16 Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods

Country Status (11)

Country Link
EP (1) EP0977583B1 (https=)
JP (1) JP4086908B2 (https=)
CN (1) CN1202862C (https=)
AT (1) ATE223229T1 (https=)
AU (1) AU7132798A (https=)
CA (1) CA2286098C (https=)
DE (1) DE69807679T2 (https=)
ES (1) ES2183351T3 (https=)
HU (1) HU226175B1 (https=)
IL (1) IL132380A0 (https=)
WO (1) WO1998046257A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
EP1128840A1 (en) * 1998-10-27 2001-09-05 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
JP2004525621A (ja) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
JP4606161B2 (ja) 2002-05-21 2011-01-05 アムジエン・インコーポレーテツド 置換複素環式化合物および使用方法
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP2647706B1 (en) * 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
PT3074033T (pt) 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
HUE063647T2 (hu) 2016-09-12 2024-01-28 Amryt Pharmaceuticals Inc Eljárások anti-leptin semlegesítõ antitestek detektálására
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods

Also Published As

Publication number Publication date
WO1998046257A1 (en) 1998-10-22
CA2286098C (en) 2009-07-07
HU226175B1 (en) 2008-06-30
WO1998046257A8 (en) 2000-01-27
EP0977583B1 (en) 2002-09-04
HUP0002831A3 (en) 2005-11-28
HK1023513A1 (en) 2000-09-15
CN1274289A (zh) 2000-11-22
CA2286098A1 (en) 1998-10-22
ES2183351T3 (es) 2003-03-16
JP4086908B2 (ja) 2008-05-14
EP0977583A1 (en) 2000-02-09
HUP0002831A2 (hu) 2000-12-28
ATE223229T1 (de) 2002-09-15
AU7132798A (en) 1998-11-11
JP2002512612A (ja) 2002-04-23
DE69807679D1 (de) 2002-10-10
CN1202862C (zh) 2005-05-25
DE69807679T2 (de) 2003-07-31

Similar Documents

Publication Publication Date Title
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
DE69432758D1 (en) Therapeutisch wirksame peptidderivate
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP1439193A3 (en) Antibody directed to polypeptide having heparanase activity
EP1752465A3 (en) Linear VH-CH1-VH-CH1 heavy chain antibody fragment
ATE204480T1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
EP1329459A3 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
DE69636923D1 (de) Katalytischer antikörper gegen aldolase
CA2246715A1 (en) Antibody variants
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
AU2236795A (en) Afamin: a human serum albumin-like protein
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST MxA OF HUMAN Mx PROTEIN
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
CA2128833A1 (en) P53as protein and antibody therefor
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
EP0918796A4 (en) MONOCLONAL ANTIBODY FOR AGGLUTINATION BY E. COLI, CONTAINING A PROTEIN FROM THE CS4 / CFA FAMILY
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
ATE293996T1 (de) Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren
AU2002300605A1 (en) Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
NZ314010A (en) A method of targeting intracellular binding proteins using a lipidized antibody

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed